INAD gene therapy is one step closer

INAD gene therapy is one step closer

Abridged translation of an English article by Patricia Wood

Work on a gene therapy for Infantile Neuroaxonal Dystrophy, known as INAD, received a major boost in October when a London-based biotech company announced its intention to help bring the therapy to market.

London-based Bloomsbury Genetic Therapies Limited, known as Bloomsbury, is to advance its efforts with the help of £5 million seed funding from the UCL Technology Fund. Bloomsbury is working on an adeno-associated virus (AAV)-based gene therapy called BGT-INAD for the treatment of INAD.

INAD is a form of PLA2G6-associated neurodegeneration or PLAN, which usually occurs between the ages of 6 months and 3 years and progresses rapidly. Many affected children do not survive their first decade of life. (...)

Bloomsbury benefits from the expertise of its academic scientists in the fields of gene therapy and rare diseases, including Professors Manju Kurian and Ahad Rahim from University College London. Kurian and Rahim have been working on a gene therapy treatment for INAD for eight years. The NBIA Disorders Association awarded the researchers a grant of USD 150,000 in 2014 to begin their work. This was followed by 655,000 pounds from the UK Medical Research Council.

Image: Researchers from University College London at the 8th International NBIA Symposium in October 2022, where they presented their work.
L-R: Professor Ahad Rahim, Dr. Apostolos Papandreou, Dr. Audrey Soo, Professor Manju Kurian, Dr. Robert Spaull.

Rahim presented the promising data for BGT-INAD at the 8th International NBIA Symposium in Lausanne in October 2022. Preliminary results show a significant improvement in survival and behavioral parameters in mice treated with BGT-INAD.

Dr. Audrey Soo, who is part of Professor Kurian's research group at UCL, also gave an update on preparations for a clinical gene therapy trial with BGT-INAD at the symposium. She said the work is based on a large retrospective natural history study of more than 300 INAD patients worldwide. (...)

UCL research has improved knowledge of INAD, including its key features and symptoms. Most importantly, researchers have developed a meaningful disease-specific rating scale for INAD and discovered potential biomarkers for blood and CSF. Once fully confirmed, the biomarkers can be used as outcome measures in clinical trials, accelerating the development and approval of potential treatments for INAD patients. Soo said she will continue the development and validation of INAD biomarkers throughout 2023.

Bloomsbury is working with researchers on an accelerated timeline to advance its gene therapy research programs into clinical trials as quickly as possible. Bloomsbury plans to complete the comprehensive efficacy evaluation for BGT-INAD in the INAD mouse model in the first quarter of 2023. The company will then focus on the required animal safety testing. It hopes that the accelerated clinical trial design will shorten the time to approval by regulatory authorities such as the European Medicines Agency or the US Food and Drug Administration so that it can make the therapy commercially available to treat patients.
Bloomsbury keeps its website up to date so that patients and relatives can find the latest information at https://bloomsburygtx.com about the latest developments. (...)

Full original version of the article and image source in the December 2022 newsletter of the NBIA Disorders Association, p. 6/7):
https://www.nbiadisorders.org/news-events/nbia-newsletters/62-2022-newsletters/477-2022-december-newsletter
Translated with the support of www.DeepL.com/Translator (free version)

Fernsehbeitrag auf 3sat zu seltenen Erkrankungen und BPAN

Fernsehbeitrag auf 3sat zu seltenen Erkrankungen und BPAN

Zum Tag der Seltenen Erkrankungen, dem 28.02.2023, widmete sich die Wissenschaftssendung NANO des Senders 3sat den Seltenen am Beispiel BPAN. Im Rahmen der Sendung war ein Filmteam bei Familie Nielbock mit Tochter Milly (https://www.millys-mission.de) zu Hause. Außerdem wurde eine der führenden BPAN-Forscherinnen, Prof. Tassula Proikas-Cezanne, von der Uni Tübingen interviewt. Selten haben wir eine so tolle Gelegenheit, auf eine NBIA-Erkrankung aufmerksam zu machen. Vielen Dank an alle Mitwirkenden und an das Team von NANO!

Die Sendung ist in der Mediathek verfügbar:

https://www.3sat.de/wissen/nano/230228-sendung-seltene-krankheiten-im-leid-allein-gelassen-nano-100.html

 

Milly mit Familie, Foto: Sonja Epple

Two MPAN project grants totaling $140,000 awarded

Two MPAN project grants totaling $140,000 awarded

Hoffnungsbaum e.V. has awarded two MPAN Fellowships in partnership with three sister organizations in Europe and the U.S. to advance research priorities in the field of mitochondrial membrane protein-associated neurodegeneration (MPAN) identified during an expert workshop on MPAN. MPAN is one of the four most common suptypes from the disease group, the generic term of which is "neurodegeneration with iron storage in the brain".

Dr. Lena F. Burbulla of the Ludwig-Maximilians-University in Munich and Dr. Rajnish Bharadwaj of the University of Rochester in New Jersey (USA) each received one-year research grants of $70,000 to study MPAN.

The financing was made possible by an international cooperation involving Hoffnungsbaum e.V. the NBIA Disorders Association in the USA, Associazione Italiana Sindromi Neurodegenerative da Accumulo di Ferro (AISNAF) in Italy and Stichting Ijzersterk in the Netherlands were also involved.

In a workshop at the end of 2020 led by Dr. Francesca Sofia, founder and CEO of Science Compass in Milan, Italy, the researchers jointly discussed a research strategy for MPAN based on existing research data and evaluated strengths, challenges and trends in MPAN research to establish a set of scientific priorities. Details can be found here: https://www.hoffnungsbaum.de/aktuelle-ausschreibung-einer-mpan-foerderung/

 

Dr. Lena F. Burbulla from the Ludwig-Maximilians-University in Munich

Mitochondria, dopamine metabolism and alpha-synuclein

Burbulla's research involves modeling human disease by creating the patient's own cells to discover new mechanisms underlying the pathology of MPAN. To do this, her lab uses induced pluripotent stem cells (iPSCs) derived from skin cells from people with MPAN. Burbulla's team will use these stem cells — which can theoretically be turned into any type of cell in the body — to create dopaminergic nerve cells called neurons, which are known to be affected in the brains of MPAN patients. Dopaminergic nerve cells produce the neurotransmitter dopamine, a chemical messenger involved in regulating body movements, memory, motivation, attention, learning, and more.

Mutations in a particular gene, C19orf12, are the only known cause of MPAN. The function of the gene-controlled protein C19orf12 is still largely unknown. Using disease modelling approaches, the researchers will use a patient-specific model to investigate the function of the C19orf12 protein, in particular how the loss of this protein affects brain cells. Burbulla and her team want to find out how the loss of C19orf12 function affects the health of the mitochondria in these patients' nerve cells. Mitochondria are the "powerhouses of the cell" that produce about 90% of the energy cells need to survive. When mitochondria are damaged, it can have catastrophic consequences for the cell, triggering a series of toxic events that eventually lead to the death of the nerve cells. Since the C19orf12 protein is known to be associated with mitochondria, its loss of function could affect mitochondria and have far-reaching effects on cell health and resilience.

The stem cell model will allow the researchers to compare the MPAN cells with healthy cells and better understand the role of the protein. They will also look beyond the mitochondria for disease-related pathology and study possible changes in the processing of the neurotransmitter dopamine in these nerve cells, as well as a protein called alpha-synuclein, which is known to pathologically accumulate in the brains of MPAN patients.

Alpha-synuclein is located at the ends of nerve cells in the synaptic cleft – the area between neurons where neurotransmitters are released to relay messages throughout the body. Abnormally shaped or excessively abundant alpha-synuclein leads to aggregation or clumping of proteins and inhibits the normal function of neurons.

 

Dr. Rajnish Bharadwaj from the University of Rochester in New Jersey (USA)

Knockout Flying, Lipid Metabolism and Mitochondrial Function

Baharadwaj's research will focus on better understanding the proteins produced by the C19orf12 gene. His team will use models of fruit flies that have been genetically engineered to lack the CG3740 and CG11671 genes, which correspond to the C19orf12 gene in humans.

Previous studies by other groups and his ongoing work have shown that the fly models have a shorter life expectancy, movement deficits, and a loss of neurons in the brain and retina. This suggests that the fruit flies are a promising model for studying NBIA.

The team's studies also suggest that C19orf12 is a membrane junction protein that may be involved in communication between organelles, specialized subunits within the cell, such as the endoplasmic reticulum and lipid droplets (fats). In the cell, the endoplasmic reticulum is responsible for producing proteins and is involved in the production and storage of lipids.

The team's goal is to investigate how the C19orf12 protein is involved in lipid metabolism and mitochondrial function. Lipid metabolism is the process of producing and breaking down lipids or fats in cells. The researchers want to uncover this role in the brain and other organs. Both lipid metabolism and mitochondrial function are also involved in other forms of NBIA.

Overall, the creation and study of these disease models and the research based on them will improve the understanding of MPAN and pave the way for the much-needed development of treatments.

 

Source: Article "Two MPAN grants worth $140,000 awarded to further disease insights" in the NBIA Disorders Association's December 2022 newsletter. We thank you for your kind permission to use the content of the article. Translations using the free version of https://www.deepl.com/translator

October 12, 2022, online lecture: Understanding hereditary developmental disorders better - what you can learn from the natural course of the disease

October 12, 2022, online lecture: Understanding hereditary developmental disorders better - what you can learn from the natural course of the disease

Steffen Syrbe is a pediatric neurologist and Professor of Pediatric Epileptology at Heidelberg University Hospital. He has been working with children with neurodevelopmental disorders for over 15 years. During this time, he has developed a strong interest in the genetic causes of epilepsies and neurological disorders. He has helped describe various neurological genetic diseases and identified new genetic causes. Currently, one focus of his scientific work is the translation of basic research into new therapies.

A better understanding of hereditary developmental disorders - what can be learned from the natural course of the disease, using the example of BPAN

In order to be able to develop new therapies from the findings of basic research, it is important to understand the natural course of developmental disorders. Only if we know the natural course of the disease can we assess whether interventions are effective.

An overview of all online lectures can be found here: Online lectures

Prof. Dr. med. Steffen Syrbe

Outpatient clinic for children with therapeutic epilepsy at the Heidelberg Social Pediatric Center

More info...

 

 

 

 

Subscribe to our Hoffnungsbaum newsletter!

With our newsletter e-mails you will receive valuable information about NBIA. If you would like to receive additional information on individual NBIA variants or special information for researchers/clinicians in addition to the general newsletter, please click here: Subscribe to additional information

Privacy policy

You have successfully registered!